Mice dosed with Sorafenib for three weeks had significantly smaller tumor volumes than mice dosed with the vehicle control (Figure 4B), whereas exposure to DCP resulted in a significant increase in tumor volume from day 15 (Figure 4B). This evidence concerns the gene ACE and neoplasm.